This is an early access version
PHI Hospital “Sveti vračevi” Bijeljina, Bosnia and Herzegovina,
Department of Primary Health Care and Public Health, Faculty of Medicine Foča, University of East Sarajevo, Bosnia and Herzegovina, Foča,
PHI Hospital “Sveti vračevi” Bijeljina, Bosnia and Herzegovina,
Department of pharmacology, Faculty of Medicine Foča, University of East Sarajevo, Bosnia and Herzegovina,
PHI Hospital “Svetivračevi” Bijeljina, Bosnia and Herzegovina,
Public Health Institute of the Republic of Srpska, Bosnia and Herzegovina,
Department of pharmacology, Faculty of Medicine Foča, University of East Sarajevo, Bosnia and Herzegovina,
Department of surgery, Faculty of Medicine Foča, University of East Sarajevo, Bosnia and Herzegovina, University hospital Foča, Republic of Srpska Bosnia and Herzegovina,
University of Belgrade, Faculty of Medicine, Belgrade, Serbia,
Department of preclinical subjects (Pathophysiology), Faculty of Medicine Foča, University of East Sarajevo, Foča, Bosnia and Herzegovina
Introduction. Antibiotic resistance is a major threat to public health globally. The aim was to examine the impact of the COVID-19 pandemic on the distribution and antimicrobial resistance of pathogenic microorganisms isolated from samples
obtained during standard hospital care in one hospital center.
Methods. Data were obtained retrospectively from a database of the hospital microbiology laboratory. Study sample consisted of 3012 samples tested before the pandemic in 2019 and 3130 samples from the pandemic period in 2021.
Results. There was no statistically significant difference in the occurrence of agents that were resistant to all antibiotics between the observed years, but there was the difference in the occurrence of those agents between departments, with the highest frequency in the intensive care unit and the COVID-19 department (p<0.001). Isolation of Acinetobacter bacteria increased 2.7 times, and Clostridioides difficile 6.4 times during 2021 compared to 2019. Statistically significant differences were registered in resistance to: imipenem, piperacillin-tazobactam, ceftayidime, cefepime, glycopeptides, aminoglycosides, levofloxacin and ciprofloxacin in 2021 compared to 2019.
Conclusion. Our results suggest possible influence of COVID-19 on antimicrobial resistance and input a need for a new larger study addressing this issue.
Data curation, N.M., B.M. and M.L.; Funding acquisition, N.M. and Z.M.; Resources, N.M. and Z.M.; Conceptualization, B.M. and N.L.; Formal Analysis, B.M., D.S., S.L. and B.J.; Investigation, B.M., D.S., S.L., D.D., N.L. and M.L.; Supervision, B.M.; Writing – original draft, B.M., D.D. and B.J.; Writing – review & editing, B.M., N.L. and B.J.; Methodology, Z.M., D.S., S.L., L.B. and D.D.; Validation, L.B.; Visualization, L.B. and N.L.; Software, D.D. and M.L. All authors have read and agreed to the published version of the manuscript.
No
No
Authors retain copyright. This work is licensed under a Creative Commons Attribution 4.0 International License. 
The statements, opinions and data contained in the journal are solely those of the individual authors and contributors and not of the publisher and the editor(s). We stay neutral with regard to jurisdictional claims in published maps and institutional affiliations.
